Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Research & Development (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Research & Development readings, the most recent being $258.2 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 39.12% to $258.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $530.7 million, a 36.57% increase, with the full-year FY2025 number at $1.0 billion, up 38.93% from a year prior.
  • Research & Development hit $258.2 million in Q4 2025 for Neurocrine Biosciences, up from $250.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $258.2 million in Q4 2025 to a low of $3.0 million in Q2 2024.
  • Median Research & Development over the past 5 years was $97.6 million (2021), compared with a mean of $99.4 million.
  • Biggest five-year swings in Research & Development: skyrocketed 1894.44% in 2022 and later plummeted 97.94% in 2024.
  • Neurocrine Biosciences' Research & Development stood at $87.4 million in 2021, then skyrocketed by 35.01% to $118.0 million in 2022, then grew by 16.53% to $137.5 million in 2023, then surged by 34.98% to $185.6 million in 2024, then surged by 39.12% to $258.2 million in 2025.
  • The last three reported values for Research & Development were $258.2 million (Q4 2025), $250.0 million (Q3 2025), and $15.0 million (Q2 2025) per Business Quant data.